Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun;74(3):210-2.
doi: 10.1007/s12262-012-0584-7. Epub 2012 Jun 20.

Oophorectomy in breast cancer-controversies and current status

Gurpreet Singh  1
Affiliations

Oophorectomy in breast cancer-controversies and current status

Gurpreet Singh. Indian J Surg. 2012 Jun.

Abstract

The role of oophorectomy in the treatment of breast cancer is known for over 100 years. Ovarian ablation has a relatively large positive effect on both disease-free survival (DFS) and overall survival (OS) in premenopausal women when compared to no adjuvant treatment. Today the standard of care in adjuvant therapy of endocrine responsive tumors in premenopausal women is tamoxifen with or without chemotherapy. The role of oophorectomy /ovarian ablation in current surgical practice is discussed and important issues highlighted in the article.

Keywords: Breast cancer; Oophorectomy; Ovarian ablation.

PubMed Disclaimer

References

    1. Love RR, Philips J. Oophorectomy for breast cancer: history revisited. J Natl Cancer Inst. 2002;94:1433–1434. doi: 10.1093/jnci/94.19.1433. - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women. N Engl J Med. 1988;319:1681–1692. doi: 10.1056/NEJM198812293192601. - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. doi: 10.1016/S0140-6736(05)66544-0. - DOI - PubMed
    1. Söreide JA, Varhaug JE, Fjösne HE, Erikstein B, Jacobsen A-B, Skovlund E, et al. Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study. Eur J Surg Oncol. 2002;28:505–510. doi: 10.1053/ejso.2002.1280. - DOI - PubMed
    1. Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist L, Fornander T. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer. Breast Cancer Res Treat. 2011;128(3):755–763. doi: 10.1007/s10549-011-1593-0. - DOI - PubMed

LinkOut - more resources